New Data from Hypertension and Amyloidosis Programs Presented at the European Society of Cardiology Congress 2025, Madrid

30 Aug, 2025 New Data from Hypertension and Amyloidosis Programs Presented at the European Society of Cardiology Congress 2025, Madrid

Presentations demonstrated the potential of RNAi therapeutics to transform the treatment of cardiovascular disease.

Pagidipati, et al. “KARDIA-3: Zilebesiran as Add-on Therapy in Adults With Hypertension Who Have Established Cardiovascular Disease or Are at High Cardiovascular Risk”

Weber, et al. “Impact of zilebesiran, an investigational RNA interference therapeutic targeting hepatic angiotensinogen, on renin–angiotensin system biomarkers in patients with mild-to-moderate hypertension”

Hanna, et al. “Vutrisiran reduces days lost to death and/or hospitalization versus placebo in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial”

Garcia-Pavia, et al. “HELIOS-B: 12-month results from the open-label extension period of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy”

Highlights include data from Cohort A of the KARDIA-3 Phase 2 study evaluating the investigational RNAi therapeutic, zilebesiran, in patients with uncontrolled hypertension and high cardiovascular risk. The data presented as a late-breaking abstract underscore the promise of zilebesiran in addressing unmet needs in hypertension and cardiovascular risk, and support the initiation of a Phase 3 cardiovascular outcomes trial.

Separately, new analyses from the ongoing Open Label Extension of the HELIOS-B Phase 3 study of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) were presented. The results demonstrate the sustained benefit of vutrisiran across mortality, cardiovascular events, quality of life, and cardiac biomarkers through up to 48 months of treatment.